Sunshine Biopharma (SBFM) Cost of Revenue (2018 - 2026)

Sunshine Biopharma has reported Cost of Revenue for 9 years, with the latest figure at $250223.0 in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 95.95% year-over-year to $250223.0; the trailing twelve-month figure through Mar 2026 stood at $29.7 million (up 1442.64% YoY), and the FY2025 full-year result was $24.1 million, up 2457.78% from the prior year.
• Cost of Revenue for Q1 2026 stood at $250223.0, down from $23.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $23.2 million in Q4 2025, with the low at -$16.8 million in Q4 2024.
• Historically, Cost of Revenue has averaged $3.3 million across 5 years, with a median of $250223.0 in 2026.
• Annual changes were most pronounced in 2023 — Cost of Revenue soared 8482.28% — and 2024, when it slumped 209.91%.
• Sunshine Biopharma's Cost of Revenue stood at $177699.0 in 2022, then soared by 8482.28% to $15.3 million in 2023, then tumbled by 209.91% to -$16.8 million in 2024, then surged by 238.5% to $23.2 million in 2025, then sank by 98.92% to $250223.0 in 2026.
• The last three Cost of Revenue figures came in at $250223.0 (Q1 2026), $23.2 million (Q4 2025), and $235217.0 (Q3 2025), per Business Quant data.